- Home
- MEIP vs BPT Comparison
MEIP vs BPT Comparison
Compare MEIP & BPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- BPT
- Stock Information
- Founded
- MEIP 2000
- BPT 1989
- Country
- MEIP United States
- BPT United States
- Employees
- MEIP N/A
- BPT N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- BPT Integrated oil Companies
- Sector
- MEIP Health Care
- BPT Energy
- Exchange
- MEIP Nasdaq
- BPT Nasdaq
- Market Cap
- MEIP 13.3M
- BPT 11.7M
- IPO Year
- MEIP 2003
- BPT N/A
- Fundamental
- Price
- MEIP $2.18
- BPT $0.63
- Analyst Decision
- MEIP Hold
- BPT
- Analyst Count
- MEIP 1
- BPT 0
- Target Price
- MEIP N/A
- BPT N/A
- AVG Volume (30 Days)
- MEIP 6.4K
- BPT 76.0K
- Earning Date
- MEIP 05-13-2025
- BPT 06-17-2025
- Dividend Yield
- MEIP N/A
- BPT N/A
- EPS Growth
- MEIP N/A
- BPT N/A
- EPS
- MEIP N/A
- BPT N/A
- Revenue
- MEIP N/A
- BPT $211,000.00
- Revenue This Year
- MEIP N/A
- BPT N/A
- Revenue Next Year
- MEIP N/A
- BPT N/A
- P/E Ratio
- MEIP N/A
- BPT N/A
- Revenue Growth
- MEIP 33.76
- BPT N/A
- 52 Week Low
- MEIP $1.46
- BPT $0.40
- 52 Week High
- MEIP $4.10
- BPT $2.61
- Technical
- Relative Strength Index (RSI)
- MEIP 53.30
- BPT 52.72
- Support Level
- MEIP $2.05
- BPT $0.61
- Resistance Level
- MEIP $2.25
- BPT $0.67
- Average True Range (ATR)
- MEIP 0.11
- BPT 0.03
- MACD
- MEIP 0.00
- BPT -0.00
- Stochastic Oscillator
- MEIP 69.91
- BPT 28.57
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About BPT BP Prudhoe Bay Royalty Trust
BP Prudhoe Bay Royalty Trust is a grantor trust operating in the US. The property of the Trust consists of an overriding royalty interest. The Royalty Interest entitles the Trust to receive the royalty from the production of crude oil and condensate from the working interest of BP Exploration (Alaska) Inc. in the Prudhoe Bay oil field located on the North Slope of Alaska.